Marcel R.M. van den Brink

van den Brink obtained his M.D. and Ph.D. from the University of Leiden, completed a postdoctoral fellowship at the Pittsburgh Cancer Institute in Pittsburgh, PA and residency at Duke University Medical Center in Durham, NC. From 1994-1997, van den Brink was a Clinical Fellow in Hematology and Oncology at Beth Israel Deaconess Medical Center and a Clinical Fellow in Medicine at Harvard Medical School in Boston, MA. He then carried out a post-doctoral fellowship at the Dana Farber Cancer Institute in Boston, MA from 1995-1999.

He is now the Head of the Division of Hematologic Malignancies[2] and Alan Houghton Chair in Immunology[3] at Memorial Sloan Kettering Cancer Center (MSKCC), as well as Professor at Gerstner Sloan Kettering Graduate School of Biomedical Sciences[4] and Weill Cornell Graduate School of Medical Sciences. He is the Co-Director[5] of the Parker Institute for Cancer Immunotherapy.[6] He is also chairman of DKMS Stiftung Leben Spenden.[7]

As a physician-scientist, van den Brink studies allogeneic bone marrow transplantation both in the clinic and the laboratory. Areas in which van den Brink has published research include the development of strategies to enhance post-transplant immune reconstitution;[8] the pathophysiology of graft-versus-host disease[9] (GVHD), and intestinal microflora.[10]

• 1996 Physician Scientist Award, Howard Hughes Medical Institute
• 1999 Amy Strelzer Manasevit Scholar Award[11]
• 2001 Damon Runyon Scholar Award, Cancer Research Fund[12]
• 2004 Member of the American Society for Clinical Investigation[13]
• 2013 Member of the Association of American Physicians
• 2014 Immunology Letters Lecture Award, European Federation of Immunological Societies[14]
• 2015 Delete Blood Cancer Award, DKMS[15]
• 2015 Till and McCulloch Lectureship Award[16]
• 2020 Foreign member of the Royal Netherlands Academy of Arts and Sciences[17]

• Tsai JJ, Takahashi K, Dudakov JA, Shieh J, Singer NV, West ML, Smith OM, Young LF, Holland AM, Shono Y, Ghosh A, Tran HT, Moore MAS, van den Brink MRM. "Nrf2 regulates haematopoietic stem cell function". Nature Cell Biology. 2013; 15(3): 309-16. PMID 23434824; PMC 3699879.
• Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MRM. "IL-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft vs. host disease". Immunity. 2012; 37:339-350. (Previews in Immunity 2012; 37:196). PMID 22921121; PMC 3477611.
• Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh S, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MRM. "Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation". Journal of Experimental Medicine. 2012; 209:903-911. (Research Highlight in Nature Reviews Immunology 2012; 12:399) PMID 22547653; PMC 3348096.
• Dudakov JA, Hanash AM, Jenq RR, Young LF, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MRM. "IL-22 drives endogenous thymic regeneration in mice". Science. 2012; 336:91-95. (Perspectives in Science 2012; 336:40; Leading Edge Select in Cell 2012; 149:729) PMID 22383805; PMC 3616391.
• Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R. Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Liu C, van den Brink MRM. "Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors". Nature Biotechnology 2008; 4:453-461. (commentary in Nature Reviews in Immunology 2008; 8:321) PMID 18376399; PMC 2731996.
• Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Cabrera-Perez J, Radhakrishnan R, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MRM. "Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation". Nature Medicine 2006; 12:1039-1047. PMID 16936725.
• Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon J, van den Brink MRM. "T cells require TRAIL for optimal graft-versus-tumor activity". Nature Medicine 2002; 8:1433-1437. PMID 12426560.